(UroToday.com) The 2024 South Central AUA annual meeting included an endourology session, featuring a presentation by Dr.

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Anish Patel discussing 90-day urologic complications from pelvic ...

Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer. November 7, 2024 DNA Damage Response Alterations Predict for Neoadjuvant ...

The Case A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation ...

This case study describes the clinical, medical and administrative management of kidney cancer secondary to occupational exposure to trichloroethylene, a chlorinated solvent classified as a known ...

Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease categorized as low, intermediate, high, or very high risk, for which recurrence and progression rates and thus management ...

A. Insert catheters only for appropriate indications (see Table 2 for guidance), and leave in place only as long as needed. (Category IB) (Key Questions 1B and 2C) Further research is needed on ...

As treatments for bladder cancer (BC) become more targeted and specific, understanding the molecular underpinnings and subtypes becomes increasingly important. Technological advancements such as ...

Background For metastatic and certain advanced prostate cancer (PC), guidelines support intensified androgen deprivation therapy (ADT) as first-line (1L) systemic treatment for improved outcomes.

(UroToday.com) The 2023 ESMO annual meeting included a Presidential session, featuring a discussant presentation by Dr. Christopher Sweeney discussing the PSMAfore phase 3 trial. Dr. Sweeney started ...